Novel peptides and compositions which modulate apoptosis

Abstract

The present invention is directed to novel peptides and compositions capable of modulating apoptosis in cells, and to methods of modulating apoptosis employing the novel peptides and compositions of the invention. In one aspect, the invention is directed to a novel peptide designated the “GD domain,” which is essential both to Bak's interaction with Bcl-x L , and to Bak's cell killing function. Methods of identifying agonists or antagonists of GD domain function are provided. The GD domain is responsible for mediating key protein/protein interactions of significance to the actions of multiple cell death regulatory molecules.

1 - 27 . (canceled) 
     
     
         28 . A method of identifying an agent capable of modulating GD domain mediated heterodimerization, comprising
 carrying out a heterodimerization assay which includes a first polypeptide and a second polypeptide, wherein said first polypeptide is SEQ ID NO: 41 and said second polypeptide is Bcl-x L , and an agent;   determining whether said agent inhibits or augments heterodimerization of said first polypeptide to said second polypeptide;   wherein if inhibition or augmentation of heterodimerization is determined, it indicates that said agent is capable of modulating GD domain mediated heterodimerization.   
     
     
         29 . The method of  claim 28 , wherein said second polypeptide is labeled. 
     
     
         30 . The method of  claim 28 , wherein said second polypeptide is present in a fusion protein. 
     
     
         31 . A method of identifying an agent capable of modulating apoptosis in a cell, comprising
 assaying an ability of said agent to modulate GD domain mediated heterodimerization between a GD domain of a first polypeptide, wherein said GD domain is SEQ ID NO: 41, and a second polypeptide, wherein said second polypeptide is Bcl-x L ; wherein the GD domain mediated heterodimerization is defined by an ability of said GD domain to interact with said second polypeptide;   and measuring an increase or decrease in the GD domain mediated heterodimerization, thereby identifying said agent capable of modulating apoptosis in a cell.   
     
     
         32 . The method of  claim 31 , wherein the increase in GD domain mediated heterodimerization represents an increase in apoptosis. 
     
     
         33 . The method of  claim 31 , wherein the decrease in GD domain mediated heterodimerization represents a decrease in apoptosis.